Biohaven Pharmaceuticals Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New Haven CT United States (2014)
Status: Acquired by Pfizer (2022)

Organization Overview

First Clinical Trial
2016
NCT02960893
First Marketed Drug
2020
rimegepant
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BIOHAVEN IRELAND | BIOHAVEN PHARM | Biohaven Pharmaceutical Holding Company Ltd. | Biohaven Pharmaceuticals, Inc.